Laurus Labs FY26 Revenue Up 23% to ₹6,813 Cr

Laurus Labs reported FY26 revenue of ₹6,813 Cr, a 23% YoY growth, with EBITDA surging 64% to ₹1,826 Cr and margins expanding to 26.8%.
The CDMO division drove performance with 36% growth to ₹2,080 Cr, while Affordable Medicines grew 18% to ₹4,733 Cr.
Company declared a second interim dividend of ₹1.2 per share and plans increased capex intensity for FY27-28 across new technologies.
Laurus completed 132 quality audits without critical findings and was listed in S&P Global Sustainability Yearbook for 2024 and 2025.